Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. Lancet 393, 1745–1759 (2019).
Vina, E. R. & Kwoh, C. K. Epidemiology of osteoarthritis: literature update. Curr. Opin. Rheumatol. 30, 160–167 (2018).
Scanzello, C. R. & Goldring, S. R. The role of synovitis in osteoarthritis pathogenesis. Bone 51, 249–257 (2012).
Mathiessen, A. & Conaghan, P. G. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res. Ther. 19, 18 (2017).
Deroyer, C. et al. CEMIP (KIAA1199) induces a fibrosis-like process in osteoarthritic chondrocytes. Cell Death Dis. 10, 103 (2019).
Remst, D. F., Blaney Davidson, E. N. & van der Kraan, P. M. Unravelling osteoarthritis-related synovial fibrosis: a step closer to solving joint stiffness. Rheumatology 54, 1954–1963 (2015).
Steenvoorden, M. M. et al. Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics. Arthritis Res. Ther. 8, R165 (2006).
Hayashi, H. & Sakai, T. Biological significance of local TGF-β activation in liver diseases. Front. Physiol. 3, 12 (2012).
Koivisto, L., Bi, J., Häkkinen, L. & Larjava, H. Integrin αvβ6: Structure, function and role in health and disease. Int. J. Biochem. Cell Biol. 99, 186–196 (2018).
Kalli, A. C., Rog, T., Vattulainen, I., Campbell, I. D. & Sansom, M. S. P. The integrin receptor in biologically relevant bilayers: insights from molecular dynamics simulations. J. Membr. Biol. 250, 337–351 (2017).
Charlier, E. et al. Toward diagnostic relevance of the αVβ5, αVβ3, and αVβ6 integrins in OA: expression within human cartilage and spinal osteophytes. Bone Res. 8, 35 (2020).
Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673–687 (2002).
Munger, J. S. et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319–328 (1999).
Henderson, N. C. & Sheppard, D. Integrin-mediated regulation of TGFβ in fibrosis. Biochim. Biophys. Acta 1832, 891–896 (2013).
de Seny, D. et al. Discovery and biochemical characterisation of four novel biomarkers for osteoarthritis. Ann. Rheum. Dis. 70, 1144–1152 (2011).
Naik, M. U. & Naik, U. P. Junctional adhesion molecule-A-induced endothelial cell migration on vitronectin is integrin alpha v beta 3 specific. J. Cell Sci. 119, 490–499 (2006).
Preissner, K. T. & Reuning, U. Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin. Thromb. Hemost. 37, 408–424 (2011).
Shen, T. L. et al. The positive role of vitronectin in radiation induced lung toxicity: the in vitro and in vivo mechanism study. J. Transl. Med. 16, 100 (2018).
Tian, J., Zhang, F. J. & Lei, G. H. Role of integrins and their ligands in osteoarthritic cartilage. Rheumatol. Int. 35, 787–798 (2015).
Hayashida, M., Hashimoto, K., Ishikawa, T. & Miyamoto, Y. Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model. Int. J. Exp. Pathol. 100, 72–82 (2019).
Gundogdu, B., Yolbas, S., Yilmaz, M., Aydin, S. & Koca, S. S. Serum osteopontin and vitronectin levels in systemic sclerosis. Adv. Clin. Exp. Med. 26, 1231–1236 (2017).
Chain, D., Kreizman, T., Shapira, H. & Shaltiel, S. Plasmin cleavage of vitronectin. Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. FEBS Lett. 285, 251–256 (1991).
Zhong, J. et al. Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts. Lab. Investig. 94, 633–644 (2014).
Relic, B. et al. 15-deoxy-delta12,14-prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts. J. Biol. Chem. 279, 22399–22403 (2004).
Sengupta, S. et al. Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia 12, 837–847 (2010).
Ning, S., Nemeth, J. A., Hanson, R. L., Forsythe, K. & Knox, S. J. Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol. Cancer Ther. 7, 1569–1578 (2008).
Tak, P. P. et al. Expression of adhesion molecules in early rheumatoid synovial tissue. Clin. Immunol. Immunopathol. 77, 236–242 (1995).
Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).
Abe, M. et al. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem. 216, 276–284 (1994).
Annes, J. P., Chen, Y., Munger, J. S. & Rifkin, D. B. Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J. Cell Biol. 165, 723–734 (2004).
Cobraiville, G. et al. Validation of a new method by nano-liquid chromatography on chip tandem mass spectrometry for combined quantitation of C3f and the V65 vitronectin fragment as biomarkers of diagnosis and severity of osteoarthritis. Talanta 169, 170–180 (2017).
Maile, L. A. et al. The heparin binding domain of VTN is the region that is required to enhance insulin-like growth factor-I signaling. Mol. Endocrinol. 20, 881–892 (2006).
Maile, L. A. et al. Modulation of integrin antagonist signaling by ligand binding of the heparin-binding domain of VTN to the alphaVbeta3 integrin. J. Cell. Biochem. 105, 437–446 (2008).
Vaamonde-Garcia, C. et al. 15-Deoxy-Δ-12, 14-prostaglandin J2 acts cooperatively with prednisolone to reduce TGF-β-induced pro-fibrotic pathways in human osteoarthritis fibroblasts. Biochem. Pharmacol. 165, 66–78 (2019).
Robertson, I. B. & Rifkin, D. B. Regulation of the bioavailability of TGF-β and TGF-β-related proteins. Cold Spring Harb. Perspect. Biol. 8, a021907 (2016).
Montaldo, C. et al. Spike-in SILAC proteomic approach reveals the vitronectin as an early molecular signature of liver fibrosis in hepatitis C infections with hepatic iron overload. Proteomics 14, 1107–1115 (2014).
Tsuruta, Y., Park, Y. J., Siegal, G. P., Liu, G. & Abraham, E. Involvement of vitronectin in lipopolysaccaride-induced acute lung injury. J. Immunol. 179, 7079–7086 (2007).
Preissner, K. T. The role of vitronectin as multifunctional regulator in the hemostatic and immune systems. Blut 59, 419–431 (1989).
Bae, H. B. et al. Vitronectin inhibits neutrophil apoptosis through activation of integrin-associated signaling pathways. Am. J. Respir. Cell Mol. Biol. 46, 790–796 (2012).
Singh, B., Janardhan, K. S. & Kanthan, R. Expression of angiostatin, integrin alphavbeta3, and vitronectin in human lungs in sepsis. Exp. Lung Res. 31, 771–782 (2005).
Tomasini-Johansson, B. R., Milbrink, J. & Pejler, G. Vitronectin expression in rheumatoid arthritic synovia-inhibition of plasmin generation by vitronectin produced in vitro. Br. J. Rheumatol. 37, 620–629 (1998).
Reilly, J. T. & Nash, J. R. Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue. J. Clin. Pathol. 41, 1269–1272 (1988).
Koukoulis, G. K., Shen, J., Virtanen, I. & Gould, V. E. Vitronectin in the cirrhotic liver: an immunomarker of mature fibrosis. Hum. Pathol. 32, 1356–1362 (2001).
Courey, A. J. et al. The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood 118, 2313–2321 (2011).
Bandyopadhyay, A. & Raghavan, S. Defining the role of integrin alphavbeta6 in cancer. Curr. Drug Targets 10, 645–652 (2009).
Landen, C. N. et al. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 10, 1259–1267 (2008).
Horton, M. A. The alpha v beta 3 integrin “vitronectin receptor”. Int. J. Biochem. Cell Biol. 29, 721–725 (1997).
Hapke, S. et al. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J. Biol. Chem. 276, 26340–26348 (2001).
Horan, G. S. et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am. J. Respir. Crit. Care Med. 177, 56–65 (2008).
Popov, Y. et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J. Hepatol. 48, 453–464 (2008).
Schnittert, J., Bansal, R., Storm, G. & Prakash, J. Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery. Adv. Drug Deliv. Rev. 129, 37–53 (2018).
Nam, E. J. et al. Up-regulated transforming growth factor beta-inducible gene h3 in rheumatoid arthritis mediates adhesion and migration of synoviocytes through alpha v beta3 integrin: regulation by cytokines. Arthritis Rheum. 54, 2734–2744 (2006).
Sullivan, B. P., Kassel, K. M., Manley, S., Baker, A. K. & Luyendyk, J. P. Regulation of transforming growth factor-β1-dependent integrin β6 expression by p38 mitogen-activated protein kinase in bile duct epithelial cells. J. Pharmacol. Exp. Ther. 337, 471–478 (2011).
Margadant, C. & Sonnenberg, A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 11, 97–105 (2010).
Kim, K. K., Sheppard, D. & Chapman, H. A. TGF-β1 signaling and tissue fibrosis. Cold Spring Harb. Perspect. Biol. 10, a022293 (2018).
Nolte, M. A. & Margadant, C. Controlling immunity and inflammation through integrin-dependent regulation of TGF-β. Trends Cell Biol. 30, 49–59 (2020).
McCarty, J. H. αvβ8 integrin adhesion and signaling pathways in development, physiology and disease. J. Cell Sci. 133, jcs239434 (2020).
Lygoe, K. A., Wall, I., Stephens, P. & Lewis, M. P. Role of vitronectin and fibronectin receptors in oral mucosal and dermal myofibroblast differentiation. Biol. Cell 99, 601–614 (2007).
Schuliga, M., Grainge, C., Westall, G. & Knight, D. The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis. Int. J. Biochem. Cell Biol. 97, 108–117 (2018).
